Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Drug Safety

• Publication date

  2014-07-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14740338.2014.932348PMID 24961142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

  2014cited by this paper
• A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

  2014cited by this paper
• Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

  2014cited by this paper
• Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

  2014cited by this paper
• Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

  2014cited by this paper
• Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

  2014cited by this paper
• Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence

  2014cited by this paper
• PCSK9 inhibitors

  2013cited by this paper
• Is mipomersen ready for clinical implementation? A transatlantic dilemma

  2013cited by this paper
• Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

  2013cited by this paper
• The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease

  2013cited by this paper
• Pharmacotherapies for lipid modification: beyond the statins

  2013cited by this paper
• Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

  2013cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.

  2013cited by this paper
• Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

  2012cited by this paper
• Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease

  2012cited by this paper
• Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

  2012cited by this paper
• [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].

  2012cited by this paper
• Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

  2012cited by this paper
• Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis

  2012cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

  2012cited by this paper
• UvA-DARE ( Digital Academic Repository ) Dyslipidemia , sense , antisense or nonsense ?

  2011cited by this paper
• Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.

  2011cited by this paper
• Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200.

  2011cited by this paper
• Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

  2010cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Perspectives on low-density lipoprotein cholesterol goal achievement

  2009cited by this paper
• Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

  2009cited by this paper
• Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-—O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

  2009cited by this paper
• Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B

  2006cited by this paper
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

  2006cited by this paper
• Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

  2004cited by this paper
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

  2003cited by this paper

• Berberine's impact on health: Comprehensive biological, pharmacological, and nutritional perspectives

  2025influential citation
• Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials

  2025cites this paper
• Retrospective Observational Analysis in a Cohort Patients in Treatment with Alirocumab and Evolocumab: Focus on C-LDL Values

  2025cites this paper
• Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy

  2024cites this paper
• Management of Hypercholesterolemia in Patients with Coronary Artery Disease: A Glimpse into the Future

  2024cites this paper
• 2023 China Guidelines for Lipid Management.

  2023cites this paper
• PCSK9 inhibitors: current status and emerging frontiers in lipid control

  2023cites this paper
• 2023 Chinese guideline for lipid management

  2023cites this paper
• Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies

  2022cites this paper
• Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics

  2022cites this paper
• Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system

  2022cites this paper
• Systematic comparison of Mendelian randomisation studies and randomised controlled trials using electronic databases

  2022cites this paper
• Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update.

  2021cites this paper
• An Update on Pharmacotherapy of Dyslipidemia for Adults

  2020cites this paper
• Familial Hypercholesterolaemia: An Updated Overall Management

  2020cites this paper
• The New Target of Vulnerable Plaque.

  2020cites this paper
• PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders

  2020cites this paper
• Resistance training restores metabolic alterations induced by monosodium glutamate in a sex‐dependent manner in male and female rats

  2019cites this paper
• Emerging drugs for the treatment of hypercholesterolemia

  2019cites this paper
• Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data

  2019cites this paper
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

  2019cites this paper
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

  2019cites this paper
• Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia

  2018cites this paper
• Chapter 2 Berberine and Its Role in Chronic Disease

  2018cites this paper
• Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives

  2017cites this paper
• Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report

  2017cites this paper
• PCSK9 as a therapeutic target for cardiovascular disease

  2017cites this paper
• Managing the lipid profile of coronary heart disease patients

  2016cites this paper
• Disadvantages of Current LDL-cholesterol Lowering and the Role of PCSK 9 Inhibitors 4

  2016cites this paper
• Genes associated with diabetes: potential for novel therapeutic targets?

  2016cites this paper
• PCSK9 inhibitors in the prevention of cardiovascular disease

  2016cites this paper
• Berberine and Its Role in Chronic Disease.

  2016cites this paper
• Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.

  2016cites this paper
• PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.

  2016cites this paper
• Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders.

  2016cites this paper
• Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy

  2015cites this paper
• Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab

  2015cites this paper
• Homeostatic effect of p-chloro-diphenyl diselenide on glucose metabolism and mitochondrial function alterations induced by monosodium glutamate administration to rats

  2015cites this paper
• Profile of evolocumab and its potential in the treatment of hyperlipidemia

  2015cites this paper
• Profile of evolocumab and its potential in the treatment of hyperlipidemia

  2015cites this paper
• New developments in atherosclerosis : clinical potential of PCSK 9 inhibition ilaria

  2015cites this paper
• Statin potency, LDL receptors and new onset diabetes.

  2014cites this paper
• Vascular Health and Risk Management Dovepress New Developments in Atherosclerosis: Clinical Potential of Pcsk9 Inhibition

  year unknowncites this paper